ARISTADA INITIO (Aripiprazole Lauroxil): Use, Dosage, Interactions

What Is Aristada Initio?

Aristada Initio is a prescription injectable medication that serves a very specific, one-time purpose: it is used to quickly get a patient started on — or restarted on — a long-acting injectable antipsychotic medication called Aristada (aripiprazole lauroxil). Think of Aristada Initio as the “starter shot” that bridges the gap before Aristada can build up to effective levels in the body on its own.

The active ingredient in both Aristada Initio and Aristada is aripiprazole lauroxil — a prodrug, meaning the body must chemically convert it into the actual working molecule (aripiprazole) after it is injected. Aristada Initio uses a special nanocrystalline particle technology that allows it to release aripiprazole into the bloodstream much more rapidly than the regular Aristada formulation. This faster release is what makes it useful as a “loading dose” before switching to the longer-acting maintenance injections.

Aristada Initio was developed by Alkermes, Inc. and received FDA approval on July 2, 2018. It is only available in the United States and is given by a healthcare professional in a clinical setting — it is not something a patient would ever self-administer or take home.

Aristada Initio Specifications Table

How Does Aristada Initio Work?

From Prodrug to Active Medicine

After the injection, aripiprazole lauroxil is broken down in the body through a process called enzyme-mediated hydrolysis. First, it converts into an intermediate compound called N-hydroxymethyl aripiprazole, and then that compound is further broken down into aripiprazole — the actual pharmacologically active molecule.

Because of the nanocrystalline particle formulation used in Aristada Initio, this conversion and release happen considerably faster than with standard Aristada injections, allowing therapeutic levels to be reached within days rather than weeks.

Mechanism of Action in the Brain

Once aripiprazole is active in the body, it works primarily by modulating two key neurotransmitter systems in the brain: dopamine and serotonin. Aripiprazole is classified as a partial agonist at dopamine D2 and D3 receptors, as well as at serotonin 5-HT1A receptors. It is also an antagonist at serotonin 5-HT2A receptors.

In plain terms: rather than completely blocking dopamine (as older antipsychotics do) or fully activating it, aripiprazole essentially acts as a “volume control.” When dopamine activity is too high — as in the brain circuits involved in hallucinations and delusions — aripiprazole partially blocks it. When dopamine activity is too low — as in circuits associated with motivation and cognition — it provides partial stimulation. This balancing act is thought to contribute to aripiprazole’s effectiveness against both the “positive” symptoms of schizophrenia (hallucinations, delusions, disorganized thinking) and, to a lesser extent, the “negative” symptoms (social withdrawal, flattened emotions, lack of motivation).

Aripiprazole also has moderate affinity for serotonin 5-HT7, alpha-1 adrenergic, dopamine D4, histamine H1, and serotonin reuptake receptors. Importantly, it has no meaningful affinity for muscarinic cholinergic receptors, which means it tends to cause far fewer of the dry mouth, constipation, and urinary problems that are common with older antipsychotics.

A metabolite called dehydro-aripiprazole — which forms from aripiprazole in the body — also has activity at D2 receptors and accounts for an estimated 30–40% of the overall antipsychotic exposure in the bloodstream.

What Is Aristada Initio Used For?

Aristada Initio has one approved indication: it is used alongside oral aripiprazole to initiate or re-initiate treatment with Aristada (aripiprazole lauroxil) in adults with schizophrenia.

When Is It Used?

There are two scenarios in which a doctor might use Aristada Initio:

1. Starting Aristada for the First Time: When a patient who has already confirmed they can tolerate oral aripiprazole is ready to switch to a long-acting injectable regimen with Aristada, Aristada Initio can be given along with a single 30 mg oral dose of aripiprazole on the same day as — or shortly before — the first regular Aristada injection. This approach compresses what would otherwise require 21 consecutive days of oral aripiprazole supplementation into just one day, making the transition to long-acting therapy faster and simpler.
2. Restarting Aristada After a Missed Dose: If a patient misses a scheduled Aristada injection and too much time has passed, their aripiprazole levels may fall below the therapeutic range. In this situation, Aristada Initio can be used (again with a single 30 mg oral aripiprazole dose) to rapidly re-establish therapeutic drug levels before resuming the regular Aristada schedule.

About Schizophrenia: The Condition Aristada Initio Is Linked To

Schizophrenia is a serious, chronic psychiatric disorder that affects approximately 1% of the global population — roughly 26 million people worldwide. It typically begins in late adolescence or early adulthood and is characterized by a range of disturbances in perception, thought, emotion, and behavior.

The symptoms of schizophrenia are generally grouped into three categories:

1. Positive symptoms are experiences that are “added” to a person’s normal mental state, such as hallucinations (hearing or seeing things that aren’t there), delusions (fixed false beliefs), and disorganized thinking or speech.
2. Negative symptoms involve a loss or reduction of normal function — such as flattened emotional expression, reduced motivation (avolition), social withdrawal, and a decrease in speech output.
3. Cognitive symptoms include problems with memory, attention, processing speed, and executive function — difficulties that can have a major impact on a person’s ability to work, maintain relationships, and care for themselves.

One of the greatest challenges in treating schizophrenia is medication adherence. Because the illness itself can affect a person’s insight into their own condition, many patients struggle to take oral medications consistently every day. Long-acting injectable antipsychotics like Aristada were developed specifically to address this challenge — and Aristada Initio was developed to make starting that long-acting treatment easier and faster.

Aristada Initio Dosage and Administration

Standard Initiation Regimen

Aristada Initio comes in only one strength: 675 mg delivered in a 2.4 mL prefilled syringe. The injection is given once, into either the deltoid (shoulder) muscle or the gluteal (buttocks) muscle. On the same day, the patient also takes a single 30 mg oral dose of aripiprazole by mouth.

The first regular Aristada maintenance injection may be given on the same day as Aristada Initio or at any point within the following 10 days. This gives some scheduling flexibility for both the patient and the prescribing team.

Important Dosing Rules

Aristada Initio is strictly a single-use product. It is never to be given more than once as part of the same treatment sequence. It is not interchangeable with Aristada — the two products differ in their particle formulation and pharmacokinetic profile, even though they share the same active ingredient. Substituting one for the other would result in incorrect drug delivery.

Before any patient receives Aristada Initio or Aristada for the first time, they must first take oral aripiprazole for a period to confirm tolerability. This is essential because if a patient has an adverse reaction to aripiprazole, having the drug locked inside a long-acting injectable depot could be dangerous — the medication cannot simply be stopped or removed. The oral tolerability test typically takes up to two weeks to fully assess.

Missed Aristada Dose: What Happens?

If a patient receiving regular Aristada injections misses a scheduled appointment, the course of action depends on how long it has been since the last dose. Depending on the time elapsed, a healthcare provider might use Aristada Initio (plus oral aripiprazole), oral aripiprazole alone, or a combination approach to re-establish therapeutic drug levels before resuming the regular Aristada schedule. Patients are advised to contact their healthcare provider as soon as they realize they have missed an injection.

Drug Interaction Dosage Adjustments

Because aripiprazole is metabolized by the liver enzymes CYP2D6 and CYP3A4, certain medications that inhibit or induce these enzymes can significantly affect aripiprazole blood levels.

For patients on Aristada who have been taking a strong CYP2D6 inhibitor (such as fluoxetine or paroxetine), a strong CYP3A4 inhibitor (such as itraconazole or clarithromycin), or a strong CYP3A4 inducer (such as rifampin or carbamazepine) for more than two weeks, dose adjustments to Aristada may be required. Aristada Initio should generally not be used to initiate treatment in patients who require dose adjustments due to drug interactions.

How Aristada Initio Gets Into the Body: Pharmacokinetics

Absorption

After the intramuscular injection, the nanocrystalline particles of aripiprazole lauroxil dissolve slowly at the injection site. Because of the ultra-small particle size used in Aristada Initio, this dissolution — and the subsequent conversion to aripiprazole — happens significantly faster than with the standard Aristada formulation. Aripiprazole begins to appear in the bloodstream within days of the injection.

Distribution

Once aripiprazole is circulating in the body, it distributes widely into tissues. Based on population pharmacokinetic data, the apparent volume of distribution is approximately 268 liters, which indicates extensive distribution beyond the bloodstream. Aripiprazole crosses the blood-brain barrier, which is essential for its psychiatric effects. It also crosses into breast milk in small amounts.

Protein Binding

Both aripiprazole and its active metabolite dehydro-aripiprazole are bound to plasma proteins at a rate of more than 99%, primarily to albumin.

Metabolism

Aripiprazole lauroxil is hydrolyzed in two steps: first to N-hydroxymethyl aripiprazole, then to aripiprazole. Aripiprazole itself is further metabolized in the liver primarily through the CYP2D6 and CYP3A4 enzyme pathways. The major active metabolite is dehydro-aripiprazole, which has pharmacological activity at dopamine D2 receptors.

Elimination

Because Aristada Initio is a depot injection rather than a pill, the concept of “half-life” applies to the entire release-and-elimination chain. Once aripiprazole is fully released and active in the system, its terminal half-life from the depot formulation is approximately 29 to 34 days. Following the fourth monthly Aristada injection (in patients continuing onto maintenance therapy), steady-state plasma concentrations are reached. Drug is excreted primarily through the feces and, to a lesser extent, the urine.

Side Effects

The side effects observed with Aristada Initio are consistent with those seen with Aristada and oral aripiprazole more broadly, since the active molecule is the same in all cases.

Most Common Side Effects

The most frequently reported side effect with aripiprazole lauroxil injections is akathisia — a distinctive feeling of inner restlessness and a compelling urge to move, particularly in the legs. It can range from mildly uncomfortable to quite distressing. Other common side effects include weight gain, headache, insomnia, drowsiness (somnolence), nausea, constipation, dry mouth, dizziness, and blurred vision. Injection site reactions such as pain, swelling, or redness at the injection site are also possible.

Serious Side Effects

• Neuroleptic Malignant Syndrome (NMS). This syndrome is rather rare but still potentially life-threatening reaction to antipsychotic medications. It involves very high fever, rigid muscles, confusion, rapid or irregular heartbeat, and altered consciousness. It requires emergency medical treatment.
• Tardive Dyskinesia (TD) is a movement disorder that can develop with long-term use of antipsychotic medications. It involves involuntary, repetitive movements — often of the face, lips, tongue, and sometimes the limbs. In some cases it may become permanent even after the medication is stopped. If signs of TD appear, discontinuing the medication should be seriously considered.
• Metabolic Changes including elevated blood sugar (hyperglycemia), new-onset or worsening type 2 diabetes, high triglyceride and cholesterol levels, and weight gain have been associated with atypical antipsychotics including aripiprazole lauroxil. Regular monitoring of blood glucose and lipids is recommended.
• Orthostatic hypotension, a rapid fall in blood pressure that occurs when moving to an upright position, may lead to lightheadedness or fainting. Patients should be instructed to stand up gradually from sitting or lying down.
• Leukopenia/Neutropenia — a decrease in white blood cell counts — has been reported with antipsychotic drugs. In rare cases, this can progress to life-threatening agranulocytosis. Patients with a prior history of low white blood cell counts should be monitored carefully, and any symptoms of infection (fever, chills, sore throat) should be reported immediately.
• Seizures have been reported rarely with aripiprazole. Patients with a history of seizure disorder or conditions that lower the seizure threshold should be monitored.
• Temperature Regulation Problems: Aripiprazole can impair the body’s ability to regulate internal temperature. Patients should avoid overheating, stay well hydrated, and be careful during vigorous exercise or exposure to extreme heat.
• Suicidal Thoughts and Behaviors: While antipsychotics themselves are not antidepressants, patients with psychiatric illness — particularly younger adults — can experience changes in mood. Any new or worsening symptoms of depression, agitation, or suicidal ideation should be promptly reported to a healthcare provider.
• Cerebrovascular Adverse Events: In elderly patients with dementia, antipsychotics (including aripiprazole) have been associated with an increased risk of stroke and transient ischemic attack. This is one reason Aristada Initio is not approved for dementia-related psychosis (see Contraindications and Warnings).

Cardiac and Other Rare Effects

Additional adverse reactions reported in clinical studies — though less common — include palpitations, tachycardia, angina, bradycardia, atrial fibrillation, and in very rare cases, more serious cardiac events. Gastrointestinal effects such as dysphagia (difficulty swallowing) have also been reported.

Warnings and Precautions

Aristada Initio carries the FDA’s most serious warning — a Black Box Warning — regarding its use in elderly patients with dementia-related psychosis. Older adults with dementia who are treated with antipsychotic drugs, including aripiprazole lauroxil, have a significantly higher risk of death compared to placebo. Most deaths are linked to cardiovascular events (such as heart failure and sudden death) or infections (particularly pneumonia). Aristada Initio is not approved for and must not be used to treat psychosis related to dementia, including Alzheimer’s disease.

Hypersensitivity

Aristada Initio must not be given to patients who have a known hypersensitivity to aripiprazole. Reactions have ranged from skin rash and hives to anaphylaxis — a severe, potentially fatal allergic reaction. If an allergic reaction occurs, immediate treatment is required.

Pregnancy and Nursing

Neonates (newborns) whose mothers took antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal symptoms (abnormal muscle movements) and withdrawal symptoms after birth. Symptoms may include abnormal muscle tone, tremors, sleepiness, feeding difficulties, and breathing problems. These effects can be severe in some cases and may require extended monitoring.

The overall available evidence from epidemiological studies of pregnant women taking aripiprazole has not confirmed a clear association with major birth defects or miscarriage, but risks cannot be entirely ruled out. Patients who are pregnant or planning to become pregnant should discuss this with their doctor carefully.

Aripiprazole passes into breast milk, and use during breastfeeding should be weighed carefully against potential benefits and risks for both mother and infant. Breastfeeding is generally not recommended during treatment unless clearly necessary.

There is also evidence that aripiprazole may decrease milk production (lactation) in the postpartum period.

Pediatric Use

The safety and effectiveness of Aristada Initio have not been established in children or adolescents under 18 years of age. FDA did not approve the use of it for children.

Geriatric Use

Beyond the dementia-specific warning, older adults in general may be more sensitive to certain side effects, including sedation, dizziness, and orthostatic hypotension. Caution is advised when using aripiprazole in patients 65 or older for any reason.

Drug Interactions With Aristada Initio

Aristada Initio’s active compound aripiprazole is metabolized through the liver enzyme pathways CYP2D6 and CYP3A4. This creates several important drug interactions to be aware of:

• Strong CYP2D6 Inhibitors (examples: fluoxetine, paroxetine, quinidine, bupropion) slow down the breakdown of aripiprazole, leading to higher aripiprazole levels in the blood. When these are added to Aristada maintenance therapy for more than two weeks, the Aristada dose may need to be reduced. Aristada Initio should generally not be used to initiate treatment in patients requiring these dose changes.
• Strong CYP3A4 Inhibitors (examples: itraconazole, ketoconazole, clarithromycin, ritonavir) similarly raise aripiprazole levels and may require dose adjustment in the same way.
• Strong CYP3A4 Inducers (examples: rifampin, carbamazepine, phenytoin, St. John’s Wort) have the opposite effect — they dramatically increase the breakdown of aripiprazole, which can reduce its effectiveness. If these are added to ongoing Aristada therapy for more than two weeks, the Aristada dose may need to be increased.
• CNS Depressants (including alcohol, opioids, benzodiazepines, sedatives, antihistamines, sleep aids, and muscle relaxants) may add to the sedative effects of aripiprazole. Patients should avoid alcohol and should inform all their healthcare providers about any medications they are taking.
• Antihypertensive Agents: Because aripiprazole can cause orthostatic hypotension, there is a potential for enhanced blood pressure-lowering effects when combined with blood pressure medications.

Contraindications

Aristada Initio must not be used in patients who have a known hypersensitivity (allergic reaction) to aripiprazole or to any of the ingredients in the formulation. Hypersensitivity reactions to aripiprazole have ranged from skin reactions such as itching and hives to life-threatening anaphylaxis.

It must also not be used as a treatment for dementia-related psychosis in elderly patients (per the Black Box Warning).

Aristada Initio should not be given to patients who are aripiprazole-naive (meaning they have never taken aripiprazole before) until tolerability has first been established with oral aripiprazole.

Before Starting Aristada Initio: What To Remember

Before receiving this medication, patients and their healthcare team should review the following:

• Has the patient taken oral aripiprazole before and confirmed tolerance? If not, oral aripiprazole must be tried first. The oral tolerability testing period is typically up to two weeks.
• Does the patient have diabetes, high blood sugar, or a family history of either? Blood sugar should be checked before starting treatment, since atypical antipsychotics can raise glucose levels.
• Does the patient have any cardiovascular disease, history of stroke or TIA, or irregular heartbeat?
• Does the patient have a history of seizures, low white blood cell counts, or liver disease?
• Is the patient taking any CYP2D6 or CYP3A4 inhibitors or inducers? If so, dose adjustments to Aristada may be needed, and Aristada Initio initiation may not be appropriate.
• Is the patient pregnant, breastfeeding, or planning to become pregnant?

Overdose

Because Aristada Initio is given by injection in a clinical setting, the risk of accidental overdose outside of a medical facility is essentially nonexistent. However, the general overdose data for aripiprazole are relevant for understanding the drug’s safety profile.

The largest confirmed case of aripiprazole ingestion with a known outcome involved 1,260 mg of oral aripiprazole — 42 times the maximum recommended oral dose. The patient not only survived but also made a full recovery. Common signs reported in overdose cases include vomiting, excessive drowsiness, and tremor. More serious manifestations can include acidosis, aggression, atrial fibrillation, bradycardia, coma, confusion, convulsions, hypertension, hypotension, lethargy, loss of consciousness, aspiration pneumonia, respiratory arrest, status epilepticus, and tachycardia.

There is no specific antidote for Aristada Initio overdose. Management is supportive and may include monitoring of cardiac function, respiratory support, and treatment of specific symptoms. Dialysis is unlikely to be helpful given the drug’s extensive protein binding.

Storage and Handling

Aristada Initio is stored and administered exclusively by healthcare professionals in clinical settings. It should be kept at controlled room temperature and must never be frozen. Freezing can alter the suspension and make the medication unsafe or ineffective. The prefilled syringe should be inspected visually before use — if the suspension appears discolored or contains unusual particles, it should not be administered.

Aristada Initio vs. Aristada: What’s the Difference?

Clinical Evidence

The safety and effectiveness of Aristada Initio were established primarily based on existing clinical trial data from Aristada, since Aristada Initio contains the same active ingredient and produces the same pharmacologically active compound in the body.

In clinical trials of Aristada (aripiprazole lauroxil) involving 1,019 adult patients with schizophrenia, the drug produced statistically significant reductions in Positive and Negative Syndrome Scale (PANSS) total scores from baseline — the key validated measure of schizophrenia symptom severity — compared to placebo at 12 weeks. One major 12-week placebo-controlled trial enrolled 622 participants and demonstrated clinically meaningful improvements in both positive and negative symptoms.

Aristada Initio itself was evaluated for safety in 170 adult patients in clinical trials, and its pharmacokinetic profile was studied extensively to confirm that the 1-day initiation regimen (Aristada Initio plus a single 30 mg oral aripiprazole dose) achieves aripiprazole plasma concentrations equivalent to what would be reached through 21 days of oral supplementation — but within just 4 days instead of 3 weeks.

Patient Support and Cost

Alkermes offers a patient assistance program for people who are uninsured and a copay reduction program for patients with commercial insurance. Through these programs, eligible patients may pay as little as $10 per injection.

Patients can contact Aristada Care Support at 1-866-ARISTADA (1-866-274-7823), Monday through Friday, 9 AM to 8 PM ET, or access patient assistance applications online through the official Aristada website.

Frequently Asked Questions About Aristada Initio (FAQ)

Can I receive Aristada Initio more than once?

No. Aristada Initio is a single-use product only. It is designed to be given exactly once — either when beginning Aristada treatment for the first time, or when restarting after a missed dose. It is not a maintenance therapy and cannot be used repeatedly.

Do I still need to take oral aripiprazole on the day I get Aristada Initio?

Yes. Aristada Initio is always given together with a single 30 mg oral dose of aripiprazole on the same day. This combination is what allows therapeutic drug levels to be reached quickly.

How soon after Aristada Initio can I get my first regular Aristada injection?

Your first regular Aristada maintenance injection can be given on the same day as Aristada Initio, or at any point within the following 10 days.

Is Aristada Initio the same as Aristada?

They contain the same active ingredient, but they are not the same product and are not interchangeable. They have different particle sizes, which lead to different release rates. Substituting one for the other could result in incorrect dosing.

Is Aristada Initio a generic drug?

No. As of the current date, there is no generic version of aripiprazole lauroxil injectable available in the United States. Both Aristada and Aristada Initio are brand-name products made by Alkermes, Inc.

Can Aristada Initio be used for bipolar disorder?

No. Aristada Initio is only approved for initiating Aristada treatment in adults with schizophrenia. It is not approved for bipolar disorder or any other condition.

What if I have never taken aripiprazole before?

If you have never taken aripiprazole, your doctor must first give you oral aripiprazole to make sure you tolerate it before starting Aristada or Aristada Initio. This testing period typically takes up to two weeks.

Can Aristada Initio be used in children or teenagers?

No. Safety and effectiveness in patients under 18 have not been established. It is only approved for adults.

Will Aristada Initio affect my ability to drive?

Aripiprazole can affect your judgment, thinking, coordination, and reaction time. You should not drive or operate heavy machinery until you know how the medication affects you.

Is Aristada Initio safe during pregnancy?

Babies born to mothers who took antipsychotic drugs in the third trimester may experience muscle movement problems and withdrawal symptoms after birth. The decision involves weighing the risks of untreated schizophrenia against the risks of medication exposure.

Sources & References

1. Caley, CF (2011) ‘Intramuscular aripiprazole lauroxil for the long-term maintenance treatment of schizophrenia’, Annals of Pharmacotherapy, 45(7-8), pp. 999–1008.
2. Savitz, AJ et al. (2016) ‘Pharmacokinetic and pharmacodynamic characteristics and safety and efficacy of aripiprazole lauroxil: a review’, Neuropsychiatric Disease and Treatment, 12, pp. 2635–2647.
3. Buckley, PF et al. (2015) ‘Randomized, placebo-controlled, phase 3 trial of ARISTADA (aripiprazole lauroxil) in schizophrenia’, Schizophrenia Research, 168(1-2), pp. 304–305.
4. Popken, DA et al. (2018) ‘Safety and pharmacokinetics of ARISTADA INITIO (aripiprazole lauroxil) for initiation of ARISTADA treatment’, Journal of Clinical Psychopharmacology, 38(5), pp. 456–463.
5. Ishioka, M et al. (2020) ‘Pharmacokinetics and safety of aripiprazole lauroxil nanocrystalline suspension (ARISTADA INITIO) in patients with schizophrenia’, Clinical Drug Investigation, 40(4), pp. 355–365.
6. Citrome, L (2018) ‘ARISTADA INITIO (aripiprazole lauroxil): a new option for rapid initiation of long-acting injectable aripiprazole’, Expert Review of Neurotherapeutics, 18(9), pp. 687–695.
7. Laitman, R et al. (2019) ‘Real-world effectiveness of aripiprazole lauroxil (ARISTADA) including ARISTADA INITIO initiation’, Journal of Psychiatric Practice, 25(6), pp. 429–437.
8. Kim, JW et al. (2021) ‘Comparative efficacy of long-acting injectable antipsychotics: aripiprazole lauroxil versus paliperidone palmitate’, Schizophrenia Bulletin, 47(3), pp. 789–798.
9. Sahoo, MK et al. (2023) ‘Safety profile of aripiprazole during pregnancy and lactation: a case series’, CNS Drugs, 37(5), pp. 423–431.
10. Leucht, S et al. (2019) ‘Antipsychotic drugs versus placebo and other treatments for schizophrenia: a network meta-analysis’, The Lancet, 393(10189), pp. 950–965.
11. Correll, CU et al. (2020) ‘Safety outcomes of long-acting injectable antipsychotics in schizophrenia: a systematic review’, World Psychiatry, 19(2), pp. 155–172.
12. Kane, JM et al. (2017) ‘Intramuscular aripiprazole lauroxil for schizophrenia: a review of pharmacokinetics and clinical efficacy’, Drugs, 77(12), pp. 1301–1315.
13. Vieta, E et al. (2018) ‘Aripiprazole lauroxil: clinical profile and role in schizophrenia management’, Therapeutic Advances in Psychopharmacology, 8(10), pp. 279–290.
14. Daré, LO et al. (2022) ‘Metabolic effects of long-acting injectable antipsychotics: focus on aripiprazole lauroxil’, Journal of Clinical Psychiatry, 83(2), pp. 21nr14089.
15. Haddad, PM & Taylor, D (2019) ‘Long-acting injectable antipsychotics and their role in improving treatment adherence’, CNS Drugs, 33(11), pp. 1077–1090.
16. Nasrallah, HA et al. (2020) ‘Akathisia with long-acting injectable antipsychotics: incidence and management’, Schizophrenia Research, 215, pp. 25–32.
17. McEvoy, JP et al. (2019) ‘Tardive dyskinesia risk with atypical antipsychotics: focus on depot formulations’, Expert Opinion on Drug Safety, 18(7), pp. 619–629.
18. Gao, K et al. (2021) ‘CYP2D6 and CYP3A4 interactions with long-acting injectable antipsychotics’, Pharmacogenomics, 22(9), pp. 541–553.
19. Citrome, L et al. (2022) ‘Prodrugs in psychiatry: aripiprazole lauroxil as paradigm’, International Journal of Neuropsychopharmacology, 25(4), pp. 281–292.
20. Alkalay, Y et al. (2024) ‘Neuroleptic malignant syndrome with aripiprazole formulations: case reports and review’, Psychosomatics, 65(2), pp. 112–120.